New gene therapy injected into eye aims to halt rare vision loss
Disease control
Recruiting now
This study is testing a new gene therapy, AAVB-039, for people with Stargardt disease, a genetic condition that causes vision loss. The main goal is to see if a single injection into the back of the eye is safe. Researchers will also check if the treatment can slow or stop the pr…
Phase: PHASE1, PHASE2 • Sponsor: AAVantgarde Bio Srl • Aim: Disease control
Last updated Mar 09, 2026 14:23 UTC